Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in COPD
NCT03034915Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 4 trial of umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jun 2017; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03034915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03034915.